Development of zolmitriptan niosomalin-situ nasal gel

The objective of the present investigation was to development of Zolmitriptan (ZMT) niosomal in-situ nasal gel formulation for treatment of migraine. The intranasal route could delivered drug to the central nervous system (CNS) through the olfactory lobes, which helps to circumvent the blood brain barrier (BBB), which bypasses first pass metabolism and consequently enhances the bioavailability of the drug. ZMT niosomes were prepared using lipid film hydration technique. Optimized niosomal formulation was used for preparation of in situ gel formulation. The developed formulations were characterized for vesicle size, shape, zeta potential, entrapment efficiency, drug content and in-vitro diffusion study, mucoadhesive strength, permeation study, FTIR, DSC and XRD studies. The FTIR and DSC studies predicted that there was no chemical interaction between drug and excipients. ZMT niosomes were showed particle size, PDI, Zeta potential, % entrapment efficiency and drug content, 149nm, 0.223, -28.9, 88.16 0.8 % and 96.23 1.2% respectively. In vitro diffusion study of niosomes shows 96.23 0.7% at 8h. The permeation rate of in situ niosomes gel and pure drug was about 98.56% and 79.46%.